Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMRX ANIP ARDX ASRT ASND EYPT HRTX LXRX PCRX PTGX

| Held by: IJR VTI IWM VXF AVUV SPSM IJT IWO PJP CALF

Index	RUT	P/E	28.50	EPS (ttm)	1.61	Insider Own	3.32%	Shs Outstand	31.60M	Perf Week	-3.82%
Market Cap	1.45B	Forward P/E	5.32	EPS next Y	8.61	Insider Trans	-12.89%	Shs Float	30.56M	Perf Month	-1.67%
Enterprise Value	2.08B	PEG	1.21	EPS next Q	2.14	Inst Own	120.39%	Short Float	15.69%	Perf Quarter	-3.29%
Income	58.44M	P/S	1.91	EPS this Y	15.82%	Inst Trans	4.02%	Short Ratio	9.89	Perf Half Y	23.22%
Sales	757.07M	P/B	5.27	EPS next Y	15.26%	ROA	3.60%	Short Interest	4.79M	Perf YTD	-1.10%
Book/sh	8.70	P/C	4.73	EPS next 5Y	4.41%	ROE	22.96%	52W High	50.79 -9.84%	Perf Year	47.81%
Cash/sh	9.67	P/FCF	5.00	EPS past 3/5Y	0.01% -	ROIC	5.10%	52W Low	23.23 97.12%	Perf 3Y	69.91%
Dividend Est.	-	EV/EBITDA	5.35	Sales past 3/5Y	31.63% 16.31%	Gross Margin	57.22%	Volatility	3.20% 3.72%	Perf 5Y	84.64%
Dividend TTM	-	EV/Sales	2.74	EPS Y/Y TTM	-32.79%	Oper. Margin	21.47%	ATR (14)	1.68	Perf 10Y	140.49%
Dividend Ex-Date	-	Quick Ratio	1.27	Sales Y/Y TTM	26.34%	Profit Margin	7.72%	RSI (14)	46.83	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.36	EPS Q/Q	213.22%	SMA20	-1.18%	Beta	0.65	Target Price	53.67
Payout	0.00%	Debt/Eq	3.41	Sales Q/Q	31.42%	SMA50	-3.13%	Rel Volume	0.45	Prev Close	45.28
Employees	357	LT Debt/Eq	3.17	Earnings	Feb 26 BMO	SMA200	21.73%	Avg Volume	484.90K	Price	45.79
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.97% 10.70%	Trades		Volume	220,037	Change	1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$58
Jan-10-25	Upgrade	Needham	Hold → Buy	$46
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy	$47
Jun-07-24	Upgrade	Jefferies	Hold → Buy	$41 → $44
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral	$39
May-10-24	Downgrade	Needham	Buy → Hold
Jan-04-24	Downgrade	Jefferies	Buy → Hold	$30 → $37
Aug-25-23	Reiterated	Needham	Buy	$35 → $36
May-02-23	Resumed	Jefferies	Buy	$30
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$18 → $26
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$29 → $33
Jul-14-20	Initiated	BWS Financial	Sell	$8
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy	$43
Oct-30-19	Reiterated	Needham	Buy	$33 → $25
May-03-19	Resumed	H.C. Wainwright	Buy	$23
Apr-12-19	Resumed	Janney	Buy	$29
Mar-20-19	Initiated	SunTrust	Hold	$22

Show Previous Ratings

Feb-12-26 08:00AM	Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-15-26 08:00AM	Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference (GlobeNewswire)
Jan-12-26 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks) +5.73%
Jan-08-26 08:00AM	Collegium Provides 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-05-26 09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
11:22AM	Loading…
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
Dec-31-25 01:04PM	Why You Should Add Encompass Health to Your Portfolio Now (Zacks)
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
Dec-30-25 08:00AM	Collegium Announces the Closing of $980 Million Syndicated Credit Facility (GlobeNewswire)
Dec-28-25 11:01PM	2 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Dec-26-25 01:42PM	Here's Why Investors Should Hold Ensign Group Stock for Now (Zacks)
Dec-22-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? (Zacks)
Dec-18-25 11:35PM	3 Unpopular Stocks We Find Risky (StockStory)
05:12AM	Best Value Stocks to Buy for Dec. 18 (Zacks)
10:31PM	Loading…
Dec-14-25 10:31PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Dec-11-25 11:34PM	1 Growth Stock Set to Flourishand 2 Facing Challenges (StockStory)
12:51PM	MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina (Zacks)
Dec-04-25 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-03-25 03:45PM	Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 08:23AM	Collegium Pharma and Entegris have been highlighted as Zacks Bull and Bear of the Day (Zacks)
04:00AM	Bull of the Day: Collegium Pharmaceutical (COLL) (Zacks)
Nov-18-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 12:36AM	5 Revealing Analyst Questions From Collegium Pharmaceutical's Q3 Earnings Call (StockStory)
Nov-12-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.60%
Nov-07-25 09:50AM	COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook (StockStory)
03:25PM	Loading…
Nov-06-25 03:25PM	Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today (StockStory) +13.42%
02:09PM	Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:30AM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:09AM	Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1% (StockStory)
07:47AM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance (GlobeNewswire)
Nov-04-25 10:22PM	Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow (StockStory)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-29-25 08:00AM	Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment (GlobeNewswire)
Oct-23-25 08:00AM	Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
12:02AM	Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Oct-22-25 08:00AM	Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences (GlobeNewswire)
Oct-13-25 08:00AM	Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing (GlobeNewswire)
Oct-08-25 11:25AM	Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory (Insider Monkey)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-25-25 07:19PM	Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI (Zacks)
12:00PM	All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy (Zacks)
Sep-24-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Sep-23-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Argenx (ARGX) This Year? (Zacks)
Sep-02-25 04:07AM	Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 (Insider Monkey)
Aug-29-25 05:07AM	Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 (Insider Monkey)
Aug-28-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 08:00AM	Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting (GlobeNewswire)
Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 02:53PM	Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% (StockStory) +10.72%
09:30AM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:49AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook (GlobeNewswire)
Aug-06-25 05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 11:11PM	Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect (StockStory)
10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-28-25 12:01AM	3 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Jul-25-25 09:55AM	Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? (Zacks)
09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
Jul-24-25 08:00AM	Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:09PM	5 Hot Stocks With Summer Buybacks You Can Cash In On (MarketBeat)
Jul-07-25 08:00AM	Collegium Announces $150 Million Share Repurchase Program (GlobeNewswire)
Jul-01-25 02:42AM	Collegium Pharmaceutical Announces Share Repurchase Program Worth $25 Million (Insider Monkey)
Jun-30-25 06:24AM	5 Insightful Analyst Questions From Collegium Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-10-25 04:40AM	COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities (StockStory)
Jun-05-25 11:31PM	Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers (StockStory)
May-19-25 04:01PM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-25 08:05AM	Collegium Announces $25 Million Accelerated Share Repurchase Program (GlobeNewswire)
May-09-25 03:42AM	Collegium Pharmaceutical Inc (COLL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +5.94%
May-08-25 05:30PM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:11PM	Collegium Pharmaceutical: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 06:15PM	ElectroCore, Inc. (ECOR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:20PM	Collegium Pharmaceutical Q1 2025 Earnings Preview (Seeking Alpha)
10:28AM	Collegium Pharmaceutical Inc (COLL) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-28-25 12:12PM	Indivior: Trying To Break Addiction (Seeking Alpha)
09:01AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-24-25 08:00AM	Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
03:55AM	Third Avenue Small Cap Value Fund Q1 2025 Commentary (Seeking Alpha)
Apr-23-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-14-25 05:11AM	2 Reasons to Watch COLL and 1 to Stay Cautious (StockStory)
Apr-02-25 05:05AM	A Look Back at Branded Pharmaceuticals Stocks' Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack (StockStory)
Apr-01-25 08:00AM	Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 08:00AM	Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting (GlobeNewswire)
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RITA BALICE-GORDON	DIRECTOR	Dec 05 '25	Proposed Sale	47.03	3,650	171,673		Dec 17 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Option Exercise	15.90	17,600	279,840	121,213	Dec 10 04:32 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Sale	48.17	17,600	847,855	103,613	Dec 10 04:32 PM
Balice-Gordon Rita J.	Director	Dec 05 '25	Sale	47.03	3,650	171,673	52,629	Dec 09 04:22 PM
Dreyer Scott	Officer	Dec 08 '25	Proposed Sale	48.17	17,600	847,855		Dec 08 04:11 PM
Fallon John A.	Director	Nov 12 '25	Option Exercise	12.41	34,853	432,578	99,487	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Sale	47.21	34,853	1,645,536	64,634	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Proposed Sale	47.21	34,853	1,645,536		Nov 12 04:29 PM
Tupper Colleen	EVP & Chief Financial Officer	Nov 06 '25	Sale	40.53	30,000	1,215,753	126,667	Nov 07 04:23 PM
Tupper Colleen	Officer	Nov 06 '25	Proposed Sale	40.53	30,000	1,215,754		Nov 06 04:11 PM
Smith Thomas B	EVP and Chief Medical Officer	Aug 29 '25	Sale	38.42	17,478	671,576	70,264	Sep 03 04:56 PM
Smith Thomas B	Officer	Aug 29 '25	Proposed Sale	38.42	17,478	671,576		Aug 29 02:12 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Option Exercise	21.34	16,389	349,741	120,002	Aug 20 04:57 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Sale	38.21	16,389	626,171	103,613	Aug 20 04:57 PM
SANTINI GINO	Director	Aug 15 '25	Option Exercise	13.45	15,000	201,750	100,447	Aug 19 05:10 PM
SANTINI GINO	Director	Aug 15 '25	Sale	37.19	5,405	201,018	95,042	Aug 19 05:10 PM
Dreyer Scott	Officer	Aug 18 '25	Proposed Sale	38.21	16,389	626,170		Aug 18 04:50 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Option Exercise	21.34	4,861	103,734	108,474	Aug 15 05:08 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Sale	38.03	4,861	184,881	103,613	Aug 15 05:08 PM
Rubric Capital Management LP	10% Owner	Aug 13 '25	Sale	37.85	25,000	946,250	3,132,743	Aug 15 04:12 PM
SANTINI GINO	Director	Aug 15 '25	Proposed Sale	37.19	5,405	201,019		Aug 15 12:34 PM
Dreyer Scott	Officer	Aug 13 '25	Proposed Sale	38.03	4,861	184,881		Aug 13 04:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	34.36	11,659	400,641	23,129	Aug 12 05:18 PM
Heffernan Michael Thomas	Former Director	Jul 09 '25	Proposed Sale	32.17	10,328	332,269		Jul 09 04:10 PM
Heffernan Michael Thomas	Former Director	Jul 08 '25	Proposed Sale	31.38	790	24,792		Jul 08 04:19 PM
Heffernan Michael Thomas	Former Director	Jul 07 '25	Proposed Sale	31.25	14,210	444,062		Jul 07 04:43 PM
Heffernan Michael Thomas	Former Director	Jul 02 '25	Proposed Sale	30.30	25,000	757,380		Jul 02 04:50 PM
Melincoff Gwen A	Former Director	Jul 02 '25	Proposed Sale	30.29	47,082	1,425,971		Jul 02 04:35 PM
Freund John Gordon	Director	Jun 09 '25	Option Exercise	13.45	15,000	201,750	77,259	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Sale	30.62	6,601	202,149	70,658	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Proposed Sale	30.62	6,601	202,148		Jun 09 01:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 21 '25	Sale	30.03	6,396	192,069	156,667	Mar 24 05:06 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 20 '25	Sale	30.00	1,206	36,181	163,063	Mar 24 05:06 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 21 '25	Sale	30.03	18,881	566,983	103,613	Mar 24 05:05 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 20 '25	Sale	30.00	1,927	57,811	122,494	Mar 24 05:05 PM
Tupper Colleen	Officer	Mar 21 '25	Proposed Sale	30.03	6,396	192,069		Mar 21 04:35 PM
Dreyer Scott	Officer	Mar 21 '25	Proposed Sale	30.03	18,881	566,984		Mar 21 04:21 PM
Tupper Colleen	Officer	Mar 20 '25	Proposed Sale	30.00	1,206	36,181		Mar 20 04:32 PM
Kuhlmann Shirley R.	Former Officer	Mar 20 '25	Proposed Sale	29.65	40,494	1,200,632		Mar 20 04:19 PM
Dreyer Scott	Officer	Mar 20 '25	Proposed Sale	30.00	1,927	57,811		Mar 20 04:17 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 14 '25	Sale	30.00	977	29,313	164,269	Mar 18 05:35 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 14 '25	Sale	30.00	2,255	67,661	124,421	Mar 18 05:34 PM
Tupper Colleen	Officer	Mar 14 '25	Proposed Sale	30.00	977	29,313		Mar 14 04:06 PM
Dreyer Scott	Officer	Mar 14 '25	Proposed Sale	30.00	2,255	67,661		Mar 14 03:55 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	15,387	461,672	126,676	Mar 13 04:50 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 11 '25	Sale	30.01	10,445	313,413	165,246	Mar 13 04:49 PM
Tupper Colleen	Officer	Mar 11 '25	Proposed Sale	30.01	10,445	313,413		Mar 11 04:16 PM
Dreyer Scott	Officer	Mar 11 '25	Proposed Sale	30.00	15,387	461,672		Mar 11 04:08 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 06 '25	Sale	30.00	1,949	58,470	177,195	Mar 10 04:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 07 '25	Sale	30.00	1,504	45,121	175,691	Mar 10 04:02 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	3,295	98,854	144,411	Mar 10 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 07 '25	Sale	30.00	2,348	70,446	142,063	Mar 10 04:01 PM
Dreyer Scott	Officer	Mar 07 '25	Proposed Sale	30.00	2,348	70,446		Mar 07 04:21 PM
Tupper Colleen	Officer	Mar 07 '25	Proposed Sale	30.00	1,504	45,121		Mar 07 04:13 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Option Exercise	24.03	40,000	961,200	194,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Sale	28.08	40,000	1,123,160	154,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 06 '25	Sale	28.50	26,067	742,946	108,137	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 05 '25	Sale	28.03	20,000	560,528	134,204	Mar 06 06:48 PM
Tupper Colleen	Officer	Mar 06 '25	Proposed Sale	30.00	1,949	58,470		Mar 06 04:43 PM
Dreyer Scott	Officer	Mar 06 '25	Proposed Sale	30.00	3,295	98,854		Mar 06 04:31 PM
Kuhlmann Shirley R.	Officer	Mar 06 '25	Proposed Sale	28.50	26,067	742,946		Mar 06 10:42 AM
Kuhlmann Shirley R.	Officer	Mar 05 '25	Proposed Sale	28.03	20,000	560,528		Mar 05 03:03 PM
Kuhlmann Shirley R.	Officer	Mar 04 '25	Proposed Sale	28.08	40,000	1,123,160		Mar 04 04:16 PM

Open in Screener

HRTX

Heron Therapeutics Inc

Feb 13 • 04:00PM ET

1.15

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

HRTX Heron Therapeutics Inc daily Stock Chart

Peers: JNJ PFE ABBV MRK BMY GILD LLY AMGN VRTX REGN

| Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC ITOT PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	1.03%	Shs Outstand	183.32M	Perf Week	-8.73%
Market Cap	210.87M	Forward P/E	-	EPS next Y	-0.02	Insider Trans	0.00%	Shs Float	181.48M	Perf Month	-22.82%
Enterprise Value	303.68M	PEG	-	EPS next Q	-0.02	Inst Own	84.39%	Short Float	19.43%	Perf Quarter	3.60%
Income	-13.58M	P/S	1.36	EPS this Y	0.00%	Inst Trans	3.56%	Short Ratio	20.46	Perf Half Y	-14.81%
Sales	155.10M	P/B	30.02	EPS next Y	81.48%	ROA	-5.78%	Short Interest	35.26M	Perf YTD	-11.54%
Book/sh	0.04	P/C	3.80	EPS next 5Y	-	ROE	-	52W High	2.68 -57.09%	Perf Year	-30.30%
Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	65.87% 48.68%	ROIC	-8.79%	52W Low	1.00 15.01%	Perf 3Y	-55.60%
Dividend Est.	-	EV/EBITDA	68.09	Sales past 3/5Y	18.67% -0.23%	Gross Margin	73.92%	Volatility	6.30% 5.27%	Perf 5Y	-93.73%
Dividend TTM	-	EV/Sales	1.96	EPS Y/Y TTM	58.23%	Oper. Margin	1.35%	ATR (14)	0.08	Perf 10Y	-93.65%
Dividend Ex-Date	-	Quick Ratio	1.78	Sales Y/Y TTM	12.60%	Profit Margin	-8.75%	RSI (14)	34.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.56	EPS Q/Q	-223.97%	SMA20	-13.63%	Beta	1.27	Target Price	4.33
Payout	-	Debt/Eq	9.44	Sales Q/Q	16.47%	SMA50	-13.77%	Rel Volume	0.37	Prev Close	1.15
Employees	122	LT Debt/Eq	9.39	Earnings	Nov 04 BMO	SMA200	-24.92%	Avg Volume	1.72M	Price	1.15
IPO	Aug 26, 1987	Option/Short	Yes / Yes	EPS/Sales Surpr.	-566.67% -2.10%	Trades		Volume	633,849	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45

Show Previous Ratings

Jan-10-26 09:35AM	Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M (TipRanks)
Jan-09-26 09:29AM	Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth (GlobeNewswire) +9.45%
Dec-04-25 08:15AM	Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) (GlobeNewswire)
Nov-04-25 04:06PM	Heron Therapeutics Inc (HRTX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:15AM	Loading…
09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:13AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress (GlobeNewswire)
Oct-29-25 05:58PM	Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors (GlobeNewswire)
Oct-21-25 04:20PM	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire) -8.46%
Aug-15-25 07:45AM	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
Aug-09-25 03:05AM	Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Aug-08-25 09:30AM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -28.26%
08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:45AM	Loading…
07:45AM	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
07:45AM	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
06:00AM	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
Jul-28-25 09:42PM	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
Jul-07-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
May-07-25 03:38PM	Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (Seeking Alpha) -6.61%
03:04AM	Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ... (GuruFocus.com)
May-06-25 09:30AM	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks) +13.62%
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
07:53AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
07:30AM	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations (PR Newswire)
May-05-25 10:33AM	MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise (Zacks) -7.79%
May-01-25 10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
10:01AM	Loading…
Apr-29-25 10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:55PM	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-22-25 04:05PM	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire) +11.40%
10:15AM	Best Momentum Stocks to Buy for April 22nd (Zacks)
09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
07:24AM	New Strong Buy Stocks for April 22nd (Zacks)
Mar-26-25 03:57PM	Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Feb-28-25 02:08AM	Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.49%
12:56AM	Q4 2024 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:30AM	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +19.88%
07:54AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Feb-13-25 04:20PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 (PR Newswire) +7.88%
Dec-23-24 04:05PM	Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina (PR Newswire)
Dec-03-24 04:36PM	U.S. District Court Upholds Validity of CINVANTI Patents (PR Newswire) +38.98%
Nov-13-24 02:05AM	Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights (GuruFocus.com) -5.47%
Nov-12-24 10:00AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -30.43%
09:10AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:55AM	Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Nov-07-24 09:15AM	Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-24 05:00PM	Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors (PR Newswire)
Oct-29-24 04:05PM	Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 (PR Newswire) -7.33%
Oct-10-24 04:08PM	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids (PR Newswire)
Sep-25-24 08:00AM	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
Sep-03-24 08:00AM	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer (PR Newswire) -10.36%
Aug-06-24 07:30PM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -25.09%
06:45PM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Jul-30-24 04:05PM	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 (PR Newswire) +5.69%
Jul-15-24 08:00AM	Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System (PR Newswire)
Jul-11-24 12:00PM	Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.88%
Jul-02-24 08:00AM	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire) -21.04%
May-29-24 08:05AM	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
May-21-24 12:00PM	What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-24 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)
Jan-24-24 01:47PM	Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod (Benzinga) +18.86%
Jan-23-24 08:00PM	Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures (PR Newswire) -5.98%
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
09:55AM	Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-07-24 05:00PM	Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain (PR Newswire)
Dec-10-23 12:23PM	Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master (Associated Press Finance)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) -7.95% +7.00%

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rubric Capital Management LP	10% Owner	Aug 08 '25	Buy	1.50	2,387,225	3,580,838	29,100,728	Aug 12 06:00 PM
Morgan Adam	Director	Aug 08 '25	Buy	1.50	1,766,546	2,649,819	8,753,290	Aug 12 05:02 PM

Peers: EXC AEP DUK D NRG SO PEG ED FE EIX

| Held by: IJH VTI VB VBK VXF XMMO UTES MDY XMHQ VPU

Index	-	P/E	81.83	EPS (ttm)	4.60	Insider Own	0.68%	Shs Outstand	45.69M	Perf Week	9.19%
Market Cap	17.21B	Forward P/E	17.72	EPS next Y	21.26	Insider Trans	0.00%	Shs Float	45.38M	Perf Month	0.50%
Enterprise Value	19.70B	PEG	1.04	EPS next Q	2.99	Inst Own	106.25%	Short Float	5.82%	Perf Quarter	2.49%
Income	226.00M	P/S	4.24	EPS this Y	-66.43%	Inst Trans	5.75%	Short Ratio	2.86	Perf Half Y	-1.02%
Sales	4.06B	P/B	11.72	EPS next Y	258.46%	ROA	3.49%	Short Interest	2.64M	Perf YTD	0.50%
Book/sh	32.15	P/C	34.63	EPS next 5Y	17.00%	ROE	11.72%	52W High	451.28 -16.53%	Perf Year	56.71%
Cash/sh	10.88	P/FCF	93.54	EPS past 3/5Y	- -	ROIC	5.09%	52W Low	158.08 138.30%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	8.54	Sales past 3/5Y	-22.69% -	Gross Margin	68.14%	Volatility	6.14% 5.76%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.85	EPS Y/Y TTM	-74.33%	Oper. Margin	47.49%	ATR (14)	20.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.72	Sales Y/Y TTM	80.20%	Profit Margin	5.57%	RSI (14)	55.84	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.29	EPS Q/Q	34.85%	SMA20	5.90%	Beta	1.61	Target Price	466.17
Payout	0.00%	Debt/Eq	2.03	Sales Q/Q	35.08%	SMA50	2.89%	Rel Volume	0.72	Prev Close	367.81
Employees	1894	LT Debt/Eq	2.02	Earnings	Feb 26 AMC	SMA200	8.17%	Avg Volume	924.37K	Price	376.70
IPO	Jun 02, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.51% 8.92%	Trades		Volume	663,218	Change	2.42%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-28-25	Initiated	Wells Fargo	Overweight	$453
Sep-22-25	Initiated	Scotiabank	Sector Perform	$418
Aug-20-25	Initiated	Melius	Buy	$427
Jun-13-25	Initiated	Raymond James	Outperform	$314
Mar-12-25	Initiated	Morgan Stanley	Overweight	$243
Feb-21-25	Initiated	Evercore ISI	Outperform
Feb-03-25	Initiated	BofA Securities	Buy	$253
Dec-04-24	Initiated	Daiwa Securities	Buy	$248
Oct-17-24	Initiated	JP Morgan	Overweight	$268
Sep-26-24	Initiated	RBC Capital Mkts	Outperform	$233
Sep-18-24	Initiated	UBS	Buy	$197
Sep-13-24	Initiated	Jefferies	Buy	$226
Sep-04-24	Initiated	Guggenheim	Buy	$169
Aug-21-24	Initiated	Barclays	Overweight	$178

Show Previous Ratings

Feb-12-26 10:54AM	Terrestrial Energy: Nuclear Disruptor Positioned for Bull Run Initiation Report (Exec Edge)
Feb-10-26 05:32PM	Local regulators deny rezoning request for Pennsylvania data center development (Reuters)
Feb-09-26 12:05PM	Wells Fargo Highlights Talen Energy (TLN) as Key Player in PJM Colocation, Resource Adequacy Debates (Insider Monkey)
Feb-05-26 07:01AM	Talen Energy to Report Full Year and Fourth Quarter 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 05:25PM	Fluence Energy, Inc. (FLNC) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.14%
11:42AM	Loading…
Jan-26-26 11:42AM	Scotiabank Modestly Bullish on Talen Energy (TLN) Amid Attractive Valuation Following Three Gas-Fired Power Plants Acquisition (Insider Monkey)
Jan-25-26 08:02AM	DraftKings, Abbott, And Applovin Are Among Top 10 Large Cap Losers Last Week (Jan. 19-Jan. 23): Are the Others in Your Portfolio? (Benzinga)
Jan-21-26 08:39AM	Baidu and BellRing Brands have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Jan-20-26 11:04AM	Bloom Energy Outpaces Industry a Month: How to Play the Stock? (Zacks)
Jan-19-26 10:09PM	Talen Energy (TLN) Buys Three Gas-Fired Power Plants (Insider Monkey)
Jan-18-26 09:31AM	Consumer Tech News (Jan 12-16): Trump Imposes 25% Tariff on Nvidia, Eyes Starlink, Pushes $1.5T Military Budget & More (Benzinga)
Jan-16-26 04:38PM	Stocks Finish Slightly Lower as Bond Yields Climb (Barchart) -11.31%
04:28PM	Trump To Propose Tech Giants Fund Power Grid Buildouts, Energy Stocks Swing (Investor's Business Daily)
01:15PM	Russell 2000 Extends Record Run, Electricity Stocks Swing: What's Moving Markets Friday? (Benzinga)
11:53AM	Talen Energys Timing Couldnt Have Been Any Worse (24/7 Wall St.)
11:50AM	Loading…
11:50AM	These stocks have the most to lose from Trump's push to lower electricity prices (MarketWatch)
09:54AM	Stocks Climb on Renewed Optimism for AI Spending (Barchart)
09:35AM	GE Vernova shares rise as Trump, governors push for PJM power auction (Investing.com)
06:16AM	Talen Energy Corporation (TLN) Soars 11.8%: Is Further Upside Left in the Stock? (Zacks)
03:48AM	Talen in deal to buy 2.6 GW of gas plants in PJM for $3.5B (Utility Dive)
Jan-15-26 05:12PM	Amazons Big Bet: How Nuclear Power and Copper Investments Can Drive the Stock (Barrons.com) +11.80%
04:33PM	Stocks Boosted by Chip Demand Optimism (Barchart)
04:31PM	Stock Market Today: Gains Fade For Indexes, Small Caps Lead; These Breakouts Cool (Live Coverage) (Investor's Business Daily)
04:24PM	Amazon Is Channeling Henry Ford in Drive for Data-Center Dominance (Barrons.com)
03:23PM	Stock Market Today: Small Caps Lead, Some Medical Stocks Fall; BlackRock, Talen Build Bases (Live Coverage) (Investor's Business Daily)
11:14AM	Oil cools on Iran de-escalations, Talen's $3.45B gas acquisitions (Yahoo Finance Video)
10:17AM	Why Is Talen Energy Stock Gaining Thursday? (Benzinga)
10:16AM	Talen Energy Stock Jumps on $3.5 Billion Deal to 'Enhance' Data-Center Offerings (Barrons.com)
08:35AM	Another Nuclear Play Leans Into Grid Consolidation With $3.45 Billion Natural Gas Deal (Investor's Business Daily)
07:00AM	Talen Energy Continues Portfolio Expansion with Acquisition of Additional High-Quality PJM Natural Gas Assets from Energy Capital Partners (GlobeNewswire)
10:57AM	Loading…
Jan-14-26 10:57AM	Jim Cramer on Talen Energy: "I Actually Would Be Inclined to Buy Some Here" (Insider Monkey)
Jan-09-26 07:53PM	Lightning Round: Buy some Talen Energy here, says Jim Cramer (CNBC TV)
Jan-07-26 07:34AM	GE Vernova Stock Rises 13.2% in Three Months: Should You Invest Now? (Zacks)
Dec-30-25 08:30AM	Goldman Helps Lead Financing for 5-Gigawatt Texas AI Power Sites (Bloomberg)
Dec-23-25 12:29AM	Here is Why Talen Energy (TLN) Gained This Week (Insider Monkey)
Dec-22-25 09:43AM	The Zacks Analyst Blog Highlights Constellation Energy, Talen Energy and Dominion Energy (Zacks)
Dec-19-25 08:21AM	3 Nuclear Power Stocks Set to Flourish in 2026 on AI Data Center Boom (Zacks)
Dec-17-25 05:43PM	Electricity Auction Highlights Soaring Prices, Reliability Worries (Barrons.com) -6.58% +5.61%
05:05PM	Talen Energy Reports PJM Auction Results for the 2027/2028 Planning Year (GlobeNewswire)
11:59AM	BE Stock Outpaces Its Industry in the Past 3 Months: How to Play? (Zacks)
Dec-16-25 06:30AM	Biggest US Power Auction Set to Deepen Affordability Concerns (Bloomberg) +5.26%
Dec-15-25 07:00AM	Talen Energy Announces Strategic Realignment of Executive Management (GlobeNewswire)
Dec-05-25 01:28PM	Talen Energy (TLN) Falls Following a Decline in Utilities (Insider Monkey)
Dec-04-25 08:27AM	Talen Energy Corporation (TLN): A Bull Case Theory (Insider Monkey)
Dec-02-25 03:26PM	Microreactor startup Antares raises $96M for land, sea, and space-based nuclear power (TechCrunch)
Dec-01-25 11:55PM	Talen Energy (TLN) Gains Following Successful Acquisitions (Insider Monkey)
Nov-25-25 04:05PM	Talen Energy Completes Freedom and Guernsey Acquisitions (GlobeNewswire)
Nov-24-25 08:09AM	Here's What Boosted Talen Energy Corporation (TLN) in Q3 (Insider Monkey)
Nov-21-25 10:53AM	BE Stock Outperforms Its Industry in the Past Six Months: How to Play? (Zacks)
Nov-19-25 04:10PM	This $1 Billion Trump Loan For Three Mile Island Lifts S&P 500 Nuclear Giant (Investor's Business Daily) -5.48%
Nov-18-25 08:00AM	Talen Energy Receives Regulatory Clearance for Freedom and Guernsey Acquisitions (GlobeNewswire)
Nov-14-25 07:36AM	Talen Energy Corporation (TLN) Management Reiterated Its Full-Year Guidance (Insider Monkey)
Nov-13-25 01:00AM	AI Data Centers Need More Power Right Now. These Companies Can Deliver It. (Barrons.com)
Nov-07-25 04:00PM	S&P 500 Nuclear Leader Misses On Earnings. The Stock Reversed Higher. (Investor's Business Daily)
Nov-06-25 12:00AM	Talen Energy Corp (TLN) Q3 2025 Earnings Call Highlights: Strong Liquidity and Strategic ... (GuruFocus.com)
Nov-05-25 07:50PM	Talen Energy Corporation (TLN) Q3 Earnings Lag Estimates (Zacks)
06:45PM	Talen Energy: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Talen Energy Reports Third Quarter 2025 Results, Narrows 2025 Guidance (GlobeNewswire)
Nov-04-25 07:22AM	Talen Energy Corp (TLN) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 05:35PM	Ameresco (AMRC) Tops Q3 Earnings and Revenue Estimates (Zacks)
10:00AM	Will Energy Vault Holdings, Inc. (NRGV) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-30-25 09:30AM	Talen Energy, Eos Energy Partner for GWh-Scale Energy Storage in Pennsylvania to Support AI Growth (Insider Monkey)
Oct-29-25 09:40PM	Microsoft earnings offer a bullish read for power stocks (MarketWatch)
11:31AM	CEG vs. TLN: Which Power-Producer Stock Has the Stronger Outlook? (Zacks)
10:00AM	Talen Energy Corporation (TLN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-27-25 04:05PM	Talen Energy Announces Closing of $2.69 Billion Senior Notes Offerings (GlobeNewswire)
Oct-24-25 11:47AM	Trump Administration Moves to Accelerate AI Power Hookups (Bloomberg) +6.25%
Oct-22-25 08:11PM	Talen Energy Corporation (TLN): A Bull Case Theory (Insider Monkey)
08:20AM	Eos Energy to spend $353M to establish factory, relocate HQ to Pittsburgh area (Manufacturing Dive)
Oct-21-25 05:03PM	Eos Energy CEO discusses battery maker's Pennsylvania investment (Yahoo Finance Video) -6.08%
Oct-16-25 01:11PM	TLN Stock's Strategic Acquisitions to Boost Long-Term Prospects (Zacks)
08:45AM	GEV Stock Underperforms Industry in a Month: What Should Investors Do? (Zacks)
Oct-15-25 01:11PM	This low-risk sector has outperformed tech stocks this year - but it's still all about AI (MarketWatch)
01:00PM	TLN Stock Trades Above 50 & 200-Day SMAs: How to Play It Now? (Zacks)
Oct-14-25 07:00AM	Talen Energy to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-10-25 04:05PM	Talen Energy Announces Pricing of Senior Notes Offerings (GlobeNewswire) -7.12% +5.57%
01:48PM	Want a Stock Market Boost? Mention AI on Your Conference Call. (Barrons.com)
Oct-09-25 07:36AM	Talen Energy Announces Launch of Proposed Senior Notes Offerings (GlobeNewswire)
Oct-07-25 04:52AM	Talen Energy secures $1.2bn in financing for two power plant acquisitions (Power Technology)
Oct-06-25 07:41AM	Talen Energy Announces Launch of $1.2 Billion Term Loan B Financing, $200 Million Upsize of Revolving Credit Facility and $200 Million Upsize of Stand-Alone Letter of Credit Facility (GlobeNewswire)
Sep-27-25 12:58AM	Scotiabank Initiates Coverage of Talen Energy Corporation (TLN) With a Sector Perform Rating (Insider Monkey)
Sep-24-25 04:00AM	Big Tech's AI ambitions are straining the US power grid. Natural gas might be its answer. (Yahoo Finance)
Sep-23-25 11:53AM	The Zacks Analyst Blog Highlights MasTec, Comfort Systems USA and Talen Energy (Zacks)
Sep-22-25 08:08AM	3 Must-Buy Non-Tech Stocks for the Long Term Amid AI Data Center Boom (Zacks)
Sep-17-25 02:30PM	Analysts Say Talen Energy (TLN) Guidance Is 'Clearly Conservative' (Insider Monkey)
04:44AM	Zacks Investment Ideas feature highlights: Talen, Amazon, Nvidia, Constellation Energy and MasTec (Zacks)
Sep-16-25 03:45PM	3 Top AI Energy Stocks to Buy and Hold Forever (Zacks)
02:15PM	Talen Energy Corporation (TLN): A Bull Case Theory (Insider Monkey)
10:03AM	GEV Stock Wins Deal to Repower German Wind Farm: Should You Invest Now? (Zacks)
Sep-05-25 04:12PM	What AI Bubble? Vistra Makes A Powerful Run As AI Data Centers Fuel Nuclear Growth. (Investor's Business Daily)
Sep-04-25 11:43AM	Bloom Energy Outpaces Industry in a Year: How to Play the Stock? (Zacks)
Sep-03-25 08:45AM	Here's What Boosted Talen Energy Corporation's (TLN) Performance in Q2 (Insider Monkey)
Aug-27-25 12:00PM	Talen Energy Corporation (TLN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
05:42AM	Nvidia Has the Power to Move Markets Watch These Sectors. (Barrons.com)
01:01AM	BofA Maintains Buy on Talen Energy (TLN) Following Mark-to-Market Power Price Adjustments (Insider Monkey)
Aug-26-25 01:36PM	The S&P 500 Will Get a Bit More Digital When the Index Makes Its Next Change Thursday (Investopedia) +6.54%
12:06PM	This Stock Is Replacing Walgreens in the S&P 500 (Barrons.com)
11:18AM	These Stocks Are Moving the Most Today: EchoStar, AT&T, AMD, Lilly, Boeing, DJT, Talen, Semtech, and More (Barrons.com)
09:40AM	Has Tidewater (TDW) Outpaced Other Oils-Energy Stocks This Year? (Zacks)
08:02AM	Interactive Brokers To Join S&P 500; Robinhood, AppLovin Snubbed Again (Investor's Business Daily)

Talen Energy Corp. engages in the operation of power infrastructure. It produces and sells electricity, capacity, and ancillary services into wholesale power markets through its subsidiaries. The company was founded on July 2, 2014 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rubric Capital Management LP	10% Owner	Jun 27 '25	Sale	296.04	178,000	52,695,684	5,734,970	Jun 27 06:45 PM
Rubric Capital Management LP	10% Owner	Jun 25 '25	Sale	291.29	108,313	31,550,492	6,015,187	Jun 27 06:45 PM
Rubric Capital Management LP	10% Owner	Jun 26 '25	Sale	291.98	102,217	29,845,813	5,912,970	Jun 27 06:45 PM
Horton Anthony R	Director	Mar 06 '25	Buy	190.59	1,000	190,588	1,000	Mar 10 04:08 PM

COLL

Collegium Pharmaceutical Inc

HRTX

Heron Therapeutics Inc

TLN

Talen Energy Corp

Upgrade your FINVIZ experience